Genotype and risk of major bleeding during warfarin treatment.

AIM To determine whether genetic variants associated with warfarin dose variability were associated with increased risk of major bleeding during warfarin therapy. MATERIALS & METHODS Using Vanderbilt's DNA biobank we compared the prevalence of CYP2C9, VKORC1 and CYP4F2 variants in 250 cases with major bleeding and 259 controls during warfarin therapy. RESULTS CYP2C9*3 was the only allele that differed significantly among cases (14.2%) and controls (7.8%; p = 0.022). In the 214 (85.6%) cases with a major bleed 30 or more days after warfarin initiation, CYP2C9*3 was the only variant associated with bleeding (adjusted odds ratio: 2.05; 95% CI: 1.04, 4.04). CONCLUSION The CYP2C9*3 allele may double the risk of major bleeding among patients taking warfarin for 30 or more days.

[1]  D. Roden,et al.  Biobanks and Electronic Medical Records: Enabling Cost-Effective Research , 2014, Science Translational Medicine.

[2]  Munir Pirmohamed,et al.  A Randomized Trial of Genotype-Guided Dosing of Warfarin , 2014 .

[3]  B. Furie.  Do pharmacogenetics have a role in the dosing of vitamin K antagonists? , 2013, The New England journal of medicine.

[4]  R. Califf,et al.  A pharmacogenetic versus a clinical algorithm for warfarin dosing. , 2013, The New England journal of medicine.

[5]  Changqing Zeng,et al.  Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis. , 2013, International journal of cardiology.

[6]  R. Stafford,et al.  National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011 , 2012, Circulation. Cardiovascular quality and outcomes.

[7]  R. Tait,et al.  Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates , 2012, British journal of haematology.

[8]  Melissa A. Basford,et al.  Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. , 2012, Pharmacogenomics.

[9]  Munir Pirmohamed,et al.  Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy , 2011, Thrombosis and Haemostasis.

[10]  M. Whirl‐Carrillo,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing , 2011, Clinical pharmacology and therapeutics.

[11]  D. Perry,et al.  Guidelines on oral anticoagulation with warfarin – fourth edition , 2011, British journal of haematology.

[12]  W. Ray,et al.  An automated database case definition for serious bleeding related to oral anticoagulant use , 2011, Pharmacoepidemiology and drug safety.

[13]  R. Verbrugge,et al.  Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). , 2010, Journal of the American College of Cardiology.

[14]  Jenine K. Harris,et al.  Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy , 2010, Journal of thrombosis and haemostasis : JTH.

[15]  Son Doan,et al.  Application of information technology: MedEx: a medication information extraction system for clinical narratives , 2010, J. Am. Medical Informatics Assoc..

[16]  N. Limdi,et al.  Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. , 2009, Blood cells, molecules & diseases.

[17]  D. Roden,et al.  Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. , 2009, Blood.

[18]  Nicole Soranzo,et al.  A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose , 2009, PLoS genetics.

[19]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[20]  J. Lindh,et al.  Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis , 2009, European Journal of Clinical Pharmacology.

[21]  D. Roden,et al.  Development of a Large‐Scale De‐Identified DNA Biobank to Enable Personalized Medicine , 2008, Clinical pharmacology and therapeutics.

[22]  M. Rieder,et al.  An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients , 2008, Thrombosis and Haemostasis.

[23]  N. Limdi,et al.  Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. , 2008, Pharmacogenomics.

[24]  Dan M Roden,et al.  Genetic determinants of response to warfarin during initial anticoagulation. , 2008, The New England journal of medicine.

[25]  G. Mcgwin,et al.  Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African‐American and European‐American Patients on Warfarin , 2008, Clinical pharmacology and therapeutics.

[26]  Margaret Piper,et al.  A Rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding , 2008, Genetics in Medicine.

[27]  Deepak Voora,et al.  Genetic-based dosing in orthopedic patients beginning warfarin therapy. , 2007, Blood.

[28]  D. Wysowski,et al.  Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. , 2007, Archives of internal medicine.

[29]  C. Thorn,et al.  Warfarin Response and Vitamin K Epoxide Reductase Complex 1 in African Americans and Caucasians , 2007, Clinical pharmacology and therapeutics.

[30]  C. Thorn,et al.  Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. , 2007, Pharmacogenomics.

[31]  L. Alfredsson,et al.  Several‐fold increase in risk of overanticoagulation by CYP2C9 mutations , 2005, Clinical pharmacology and therapeutics.

[32]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[33]  K. Fahrbach,et al.  Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. , 2004, Chest.

[34]  Howard L McLeod,et al.  Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin , 2003, Thrombosis and Haemostasis.

[35]  M. Gent,et al.  Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.

[36]  David L Veenstra,et al.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.

[37]  H. Halkin,et al.  Interindividual variability in sensitivity to warfarin‐Nature or nurture? , 2001, Clinical pharmacology and therapeutics.

[38]  H. Echizen,et al.  Pharmacogenetics of Warfarin Elimination and its Clinical Implications , 2001, Clinical pharmacokinetics.

[39]  M. Margaglione,et al.  Genetic Modulation of Oral Anticoagulation with Warfarin , 2000, Thrombosis and Haemostasis.

[40]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[41]  Donald Martin,et al.  Risk Factors for Complications of Chronic Anticoagulation: A Multicenter Study , 1993, Annals of Internal Medicine.